Skip to content

PTC Therapeutics

US · PTCT #2071 by market cap Listed 1970
56.42 -1.91 -3.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 58.05 -0.47%
After-hours 56.99 +1.01%
89.5556.4256.422026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PTCT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -23.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 9.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 33.6x Better than 14%
Price / Sales 4.6x Better than 25%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability B

How much profit the business keeps from each dollar of sales and capital.

Gross margin 97.3% Better than 99%
Operating margin 49.5% Better than 98%
Net margin 39.4% Better than 95%
Return on equity -216.7% Better than 3%
Return on invested capital -64.1% Better than 4%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -19.2% Better than 32%
6-month return -18.0% Better than 29%
12-month return (ex latest month) -19.7% Better than 15%
Distance below 52-week high 37.9% Better than 31%
Financial Health C-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.3x Better than 63%
Debt to assets 93.4% Better than 2%
Interest coverage 5.6x Better than 59%
Free cash flow / net income 60.2% Better than 18%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 77.2% Better than 78%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.14%
1M -10.33%
3M -19.99%
6M -20.56%
YTD -25.72%
1Y -26.21%
3Y +154.49%
5Y +41.01%

Key statistics

Price & volume

Prev close
58.33
Open
58.78
Day range
56.18 - 58.96
Avg price
57.02
Volume
952.60K
Turnover
54.31M
Amplitude
4.77%
52-week range
56.18 - 90.87

Valuation

P/E
7.25
P/E (TTM)
-42.42
P/B
-24.65
EPS
7.78
Net profit
649.97M
Net assets
-191.23M

Share structure

Market cap
4.71B
Float cap
4.60B
Shares out
83.54M
Float shares
81.52M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 1% of range
56.18 90.87

37.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-15.43M net over the window

Short interest

Shares short
7.78M
As of
2026-10-30

Frequently asked questions

What is the current stock price of PTC Therapeutics (PTCT)?

PTC Therapeutics last traded at 56.42. This page shows a periodic quote snapshot. Check the displayed quote time.

What is PTC Therapeutics's market cap?

About 4.71B.

What is the P/E ratio of PTC Therapeutics?

The trailing twelve-month P/E is -42.42. The Valuation tab shows it against the stock's own five-year range.

Does PTC Therapeutics pay a dividend?

PTC Therapeutics does not currently pay a regular dividend.

Is PTC Therapeutics a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 100.00, which implies 77.2% upside from the current price. This is not investment advice.

What is PTC Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates PTC Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

PTC Therapeutics discussion 0 comments

Add a comment